• OpenVax

    Open Source Personalized Cancer Vaccines

    OpenVax is a research lab at the Icahn School of Medicine at Mount Sinai. We develop open source tools for personalized cancer vaccines. We are jointly funded by the Tisch Cancer Institute and the Department of Genetics and Genomic Sciences.

  • What's a personalized cancer vaccine?

    Personalized cancer vaccines are a form of cancer immunotherapy which target different "neoantigens" from each patient's tumor. The vaccines instruct a patient’s immune system to target his or her particular tumor. Early phase I trials have shown some success (Sahin et al. 2017, Ott et al. 2017) and many new pharmaceutical companies are forming around these vaccines.

    What's a neoantigen?

    A neoantigen is a potential determinant of immune-mediated killing which has not been previously encountered by the adaptive immune system. We are particularly interested in neoantigens arising from somatic mutations in tumor cells, since these provide an attractive target for cancer immunotherapies. You can learn more from Schumacher & Schreiber's review paper Neoantigens in cancer immunotherapy.

  • People

    B.Sc. in Computer Science from MIT
    M.Eng. in Computer Science from MIT

    B.Sc. in Computer Science from UC Berkeley

    M.Sc. in Computer Science from UC Berkeley

    B.Sc. in Math & Computer Science from Brown

    Enrolled in Ph.D. program at Mount Sinai

    B.Sc. in Neuroscience from UIUC
    M.Sc. in Computer Science from NYU

    Ph.D. in Computer Science from NYU

  • Publications

    This paper describes the sequencing protocol and computational pipeline for the PGV-001 personalized vaccine trial. PGV-001 is a therapeutic peptide vaccine targeting neoantigens identified from patient tumor samples. Peptides are selected by a computational pipeline which identifies mutations from tumor/normal exome sequencing and ranks mutant sequences by a combination of predicted Class I MHC affinity and abundance estimated from tumor RNA. The PGV pipeline is modular and consists of independently usable tools and software libraries. We hope that the functionality of these tools may extend beyond the specifics of the PGV-001 trial and enable other research groups in their own neoantigen investigations.

  • Software

    Select personalized cancer vaccine peptides from VCF + RNA

    Predict mutant MHC ligands from somatic variants

    Class I MHC binding predictor

  • Clinical Trials

    Personalized cancer vaccine trials at Mount Sinai using our software

    Principal Investigator: Nina Bhardwaj

    Safety & immunogenicity trial for the PGV-001 vaccine, which consists of 10 neoantigenic peptides injected with an adjuvant (poly-ICLC). Broad set of malignancies: H&N, NSCLC, breast, ovarian, bladder, SCC, multiple myeloma. Patients must be disease-free when beginning treatment with PGV-001, so this trial is most applicable following a complete resection.

    Principal Investigator: Adilia Hormigo

    The PGV-001 neoantigen peptide vaccine in combination with standard-of-care temozolomide and Novocure's "tumor treating fields" for glioblastoma.

    Principal Investigator: Matt Galsky

    The PGV-001 neoantigen peptide vaccine in combination with an anti-PD-L1 checkpoint agent (atezolizumab) for bladder cancer.

  • Blog

    Thoughts and research snippets

    There are no published blog posts yet.
    All Posts